OncoMatch/Clinical Trials/NCT06392295
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
Is NCT06392295 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Androgen Deprivation Therapy and Androgen Receptor Signaling Inhibitor for prostate cancer.
Treatment: Androgen Deprivation Therapy · Androgen Receptor Signaling Inhibitor — The purpose of this prostate cancer research study is to learn about: 1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy; 2. Preserving quality of life after radiation therapy; 3. Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scans to evaluate and manage disease progression.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Biomarker criteria
Required: FOLH1 PSMA PET/CT scan positive lesion (SUV > liver uptake and CT correlate)
No more than a total of 5 lesions on PSMA PET/CT scan (each lesion defined as positive with standardized uptake value (SUV) > liver uptake and CT scan correlate)
Disease stage
Metastatic disease required
Oligorecurrent disease limited to the sub-diaphragmatic region with or without pelvic lymph nodes
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: radiation therapy — pelvic/prostate
Prior pelvic radiation with disease response
Cannot have received: radiation therapy
History of prior radiation therapy outside the pelvis for prostate cancer
Cannot have received: androgen deprivation therapy
Androgen deprivation therapy (ADT) or chemotherapy in the three months prior to staging PSMA PET/CT scan (suggesting oligoprogressive disease, rather than true oligorecurrent disease) or at time of study enrollment
Cannot have received: chemotherapy
Androgen deprivation therapy (ADT) or chemotherapy in the three months prior to staging PSMA PET/CT scan (suggesting oligoprogressive disease, rather than true oligorecurrent disease) or at time of study enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06392295 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, androgen deprivation therapy, chemotherapy disqualifies patients from enrollment.
Does this trial require FOLH1?
Yes, FOLH1 PSMA PET/CT scan positive lesion (SUV > liver uptake and CT correlate) is a required biomarker for enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages